((自动化翻译由路透提供,请见免责声明 ))
11月4日 - ** Viking Therapeutics 股价盘前上涨24.59%至90.80美元
** 该公司在一次会议上公布了其实验性口服肥胖症药物VK2735的高剂量数据 (link), ObesityWeek
** 在一项早期试验中,服用 100 毫克剂量药物的患者在 28 天内体重减轻了 8.2
** 券商摩根大通称数据 "超出预期
** 极少的呕吐可能是耐受性的关键因素--券商杰富瑞(Jefferies
** 截至上次收盘,该公司股价已上涨近三倍
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.